Consent given pursuant to Sections 14 and 14A for the supply and importation of the therapeutic goods specified - Galderma Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Australian Parliament, aims to regulate the provision of therapeutic goods to ensure public health and safety. The Act establishes a comprehensive framework for the approval, registration, and monitoring of therapeutic goods, including medicines, medical devices, and blood products. The 1989 Act was introduced to address the need for a robust regulatory system to manage the safety, efficacy, and quality of therapeutic goods available in the market. The Therapeutic Goods Administration (TGA) operates under the auspices of the Department of Health and is tasked with enforcing the provisions of the Act. The policy objective of the Act is to protect and enhance public health by ensuring that therapeutic goods are of acceptable quality and pose no unacceptable risks when used according to their approved indications. On October 23, 2014, the delegate of the Secretary of the Department of Health issued a consent under sections 14 and 14A of the Therapeutic Goods Act 1989, allowing the importation and supply of a specific batch of brimonidine (MIRVASO) 3.3 mg/g (as tartrate) gel tube [AUST R 212325], which did not conform to certain labelling requirements. This consent was granted by application of Galderma Australia Pty Ltd. The batch in question had an unapproved storage temperature stated on its label, differing from the requirements set out in the Therapeutic Goods Order No. 69. The consent is conditional, requiring the company to record the distribution of the affected batch and retrieve any remaining stock after six months. The consent is effective until the specified batch is exhausted.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration under the Commonwealth of Australia's Department of Health, applies to a wide range of therapeutic goods, including medicines, medical devices, and blood and blood components. This legislation encompasses the regulation of the importation, supply, and registration of these goods, ensuring they meet required standards for safety, quality, and efficacy. The Act applies to entities and individuals involved in the manufacture, importation, supply, or advertising of therapeutic goods within Australia, extending its reach across the Commonwealth to ensure a consistent standard of therapeutic goods across the nation. The Act includes specific exclusions, such as over-the-counter complementary medicines and certain medical devices that fall under state jurisdiction, and provides for exemptions and thresholds for certain activities, particularly for small businesses and research purposes. The application and enforcement of the Act may be further detailed and refined through subordinate instruments, such as regulations and orders, which provide additional specifications and procedural details. In this instance, the consent granted under section 14 and 14A of the Act allows for the importation and supply of a specific batch of brimonidine gel, despite a non-conformance with label requirements, under strict conditions to mitigate any potential risks.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) provides the legal framework for the regulation of therapeutic goods in Australia. Section 14 and 14A of the Act (subsections 14 and 14A) allow for the delegate of the Secretary of the Department of Health to give consent for certain therapeutic goods to be imported and supplied, even if they do not fully comply with the regulatory requirements, such as labelling standards. In this instance, Galderma Australia Pty Ltd has been granted consent to import and supply brimonidine (MIRVASO) 3.3 mg/g (as tartrate) gel tube [AUST R 212325], which has an unapproved storage temperature stated on its label. This consent is effective from October 23, 2014 until the affected batch is exhausted. Under this consent, Galderma Australia Pty Ltd has specific obligations. Firstly, they are required to record the distribution of the affected batch and to retrieve any remaining stock after six months. The labels for this product, which are the same as those approved except for the storage temperature, must be those provided to the company by the Department of Health. No other changes have been made to the product, ensuring that the integrity and safety of the therapeutic good are maintained. This consent ensures that the therapeutic good can be supplied to the market under controlled conditions, while still allowing for the necessary regulatory oversight. Failure to comply with the conditions set out in the consent may result in legal consequences. While the Act does not specify the exact nature of these consequences, breaches of conditions imposed by the delegate of the Secretary could potentially lead to civil or criminal penalties. The Therapeutic Goods (Enforcement Powers) Regulations 1991 provide for various offences and penalties related to therapeutic goods, including fines and imprisonment. In this case, Galderma Australia Pty Ltd must adhere strictly to the conditions to avoid any potential legal repercussions. In summary, the Therapeutic Goods Act 1989, through sections 14 and 14A, allows for the importation and supply of therapeutic goods that do not fully comply with regulatory standards, subject to certain conditions. Galderma Australia Pty Ltd has been granted consent to supply a specific batch of brimonidine (MIRVASO) with an unapproved storage temperature label, with strict conditions governing its distribution and retrieval. Non-compliance with these conditions could result in civil or criminal penalties as outlined in the relevant regulations.